• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38780.14
  • 1.3 %
  • 496.2891
  • FTSE
  • 8271.01
  • 0.11 %
  • 8.93
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Cytek Biosciences, Inc. (CTKB) Stock Price, News & Analysis

Cytek Biosciences, Inc. (CTKB) Stock Price, News & Analysis

Currency in USD Disclaimer

$6.55

$0.09

(1.39%)

Day's range
$6.46
Day's range
$6.69
50-day range
$4.66
Day's range
$7.63
  • Country: US
  • ISIN: US23285D1090
52 wk range
$4.66
Day's range
$9.87


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 5.76
  • Piotroski Score 5.00
  • Grade Overweight
  • Symbol (CTKB)
  • Company Cytek Biosciences, Inc.
  • Price $6.55
  • Changes Percentage (1.39%)
  • Change $0.09
  • Day Low $6.46
  • Day High $6.69
  • Year High $9.87

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $8.50
  • High Stock Price Target $8.50
  • Low Stock Price Target $8.50
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.09
  • Trailing P/E Ratio -66.67
  • Forward P/E Ratio -66.67
  • P/E Growth -66.67
  • Net Income $-12,148,000

Income Statement

Quarterly

Annual

Latest News of CTKB

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Cytek Biosciences, Inc. Frequently Asked Questions

  • What were the earnings of CTKB in the last quarter?

    In the last quarter Cytek Biosciences, Inc. earnings were on Tuesday, November, 5th. The Cytek Biosciences, Inc. maker reported $0.01 EPS for the quarter, beating analysts' consensus estimates of $0.00 by $0.01.

  • What is the Cytek Biosciences, Inc. stock price today?

    Today's price of Cytek Biosciences, Inc. is $6.55 — it has increased by +1.39% in the past 24 hours. Watch Cytek Biosciences, Inc. stock price performance more closely on the chart.

  • Does Cytek Biosciences, Inc. release reports?

    Yes, you can track Cytek Biosciences, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Cytek Biosciences, Inc. stock forecast?

    Watch the Cytek Biosciences, Inc. chart and read a more detailed Cytek Biosciences, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Cytek Biosciences, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Cytek Biosciences, Inc. stock ticker.

  • How to buy Cytek Biosciences, Inc. stocks?

    Like other stocks, CTKB shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Cytek Biosciences, Inc.'s EBITDA?

    Cytek Biosciences, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Cytek Biosciences, Inc.’s financial statements.

  • What is the Cytek Biosciences, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.0629381136, which equates to approximately -6.29%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Cytek Biosciences, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Cytek Biosciences, Inc.'s financials relevant news, and technical analysis. Cytek Biosciences, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Cytek Biosciences, Inc. stock currently indicates a “sell” signal. For more insights, review Cytek Biosciences, Inc.’s technical analysis.

  • A revenue figure for Cytek Biosciences, Inc. for its last quarter?

    Cytek Biosciences, Inc. published it's last quarterly revenues at $51.50 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.